Cholangiocarcinoma: The Present and Future of Targeted Therapies

Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. CCAs tend to metastasize with early lymph node involvement lending poor surgical outcomes and need for systemic therapy. Given paucity successful therapies in these cancers, it is important understand molecular drivers develop therapeutic strategies using targeted either alone or combination. The landscape offers several new potentially targetable drivers.